This trial is testing whether adding the drug defactinib to standard chemotherapy and radiotherapy treatment for pancreas cancer will help patients live longer without the cancer progressing. Patients will be randomly assigned to either the experimental arm, which will receive defactinib, or the control arm, which will not. The first 6 patients in the experimental arm will be closely monitored for side effects before the trial continues with more patients. The primary outcome being measured is progression-free survival (PFS).